New Guidance for Treating Systemic Sclerosis-associated ILD
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
Read MoreA study in the journal Respiration showed that patients with idiopathic pulmonary fibrosis who were treated with nintedanib saw more positive outcomes.
Read More